论文部分内容阅读
目的:观察巴曲抗栓酶对急性心肌梗死(AMI)的疗效。方法:24例AMI病人(男性18例,女性6例;年龄69±s9a),其中88%为发病12h内入院。入院即刻给阿司匹林0.3g,po,qd×3d,再改为0.1g,po,qd;入院即iv输注巴曲抗栓酶20BU溶于0.9%氯化钠液100mL,1h内滴完,以后每隔1d(即入院d3,d5)再用巴曲抗栓酶10BU,1次。结果:冠状动脉再通率为50%(6h内入院者为69%),住院病死率为12%,未见出血等不良反应。用药后凝血因子I有显著降低。结论:巴曲抗栓酶治疗AMI是安全有效的。
Objective: To observe the efficacy of batroxobin on acute myocardial infarction (AMI). Methods: Twenty-four patients with AMI (18 males and 6 females; age 69 ± s9a), of whom 88% were admitted within 12 hours of onset. Admission immediately to aspirin 0.3g, po, qd × 3d, and then changed to 0.1g, po, qd; admission iv infusion of batroxobin 20BU dissolved in 0.9% sodium chloride solution 100mL, within 1h Drip finished every 1d (ie admission d3, d5) and then use batroxobin 10BU, 1 time. Results: The recanalization rate of coronary artery was 50% (69% hospitalized within 6 hours), and the in-hospital mortality rate was 12%. No adverse reaction such as bleeding was found. After treatment, coagulation factor I was significantly reduced. Conclusion: Batroxobin is safe and effective in the treatment of AMI.